These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Topiramate in essential tremor: findings from double-blind, placebo-controlled, crossover trials.
    Author: Connor GS, Edwards K, Tarsy D.
    Journal: Clin Neuropharmacol; 2008; 31(2):97-103. PubMed ID: 18382182.
    Abstract:
    OBJECTIVE: To evaluate topiramate in adults with essential tremor. METHODS: This report represents the combined results of 3 randomized, double-blind, placebo-controlled, crossover trials that followed a common protocol. Study subjects were adults (> or =18 years old) who had untreated or treated moderate to severe essential tremor involving upper extremities. Patients were randomized to a double-blind sequence of topiramate (400 mg/d or maximum tolerated dose) then placebo (n = 30) or placebo then topiramate (n = 32). A 2-week washout period separated 10-week double-blind treatment phases. Upper extremity tremor was assessed using the Fahn-Tolosa-Marin tremor rating scale (TRS). The primary efficacy measure was the TRS total score at the final visit for patients providing on-treatment data in both double-blind treatment periods. Secondary efficacy measures included change from baseline in TRS total score and in TRS subscale scores for tremor severity, motor task performance, and functional disability. RESULTS: A total of 62 patients were enrolled. Total tremor score was significantly (P < 0.0001) lower with topiramate (28.7 +/- 1.0) vs placebo (37.0 +/- 1.0). The change from baseline in TRS total and subscale scores was significantly greater (P < or = 0.005) with topiramate treatment (mean score reduction, 7.7-11.8 vs 0.08-2.0). Of the 28 patients who discontinued without completing both treatment periods, adverse events accounted for 13 of 18 discontinuations during topiramate treatment and 5 of 10 discontinuations during placebo exposure. Adverse events reported by 2 or more patients discontinuing topiramate were nausea (n = 3), paresthesia (n = 3), and concentration/attention difficulty (n = 2). CONCLUSIONS: Topiramate was associated with overall tremor reduction and improvements in tremor severity, motor task performance, and functional disability in patients with moderate to severe essential tremor.
    [Abstract] [Full Text] [Related] [New Search]